Shionogi’s Pirespa Obtains MHLW Approval
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare approved Oct. 16 Shionogi's Pirespa (pirfenidone), indicated to treat idiopathic pulmonary fibrosis. Considering 51.7 percent of clinical studies patients developed solar photosensitivity, MHLW also cautions about exposure to sunlight while taking the drug. The ministry has notified physician associations about the drug's proper use. Physicians should inform patients of the possibilities of skin cancer caused by exposure to sunlight, and patients should avoid sun burn and direct exposure to ultraviolet light. (Click here for more - Japanese language
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.